Real World Data and its Healthcare Applications Report
|出版日||ページ情報||英文 57 Pages; 17 Tables & Figures
|実環境データとその医療アプリケーションに関する調査 Real World Data and its Healthcare Applications Report|
|出版日: 2013年03月04日||ページ情報: 英文 57 Pages; 17 Tables & Figures||
The best sources of Real World Data are discussed in detail with examples of how they are currently being used.
37 detailed interviews across all stakeholders have been collated to produce the exclusive content contained in this report.
Who is best to partner with is discussed with case study examples for you to learn from.
Developing business in the pharmaceutical industry has rarely been more difficult than in recent years. High drug attrition rates and the stagnation of developed economies have caused chronic growth issues to pharmaceutical companies; these, coupled with pressure from payors who are becoming increasingly focused on price, have made for a difficult environment.
Satisfying payor needs and ensuring treatments are suitably reimbursed is a key challenge - what Real World Data stand to do is allow payors to better understand the outcomes of various treatments and only pay for those which are most beneficial to society through conditional reimbursement. Whilst conditional reimbursement is risky for pharmaceutical companies, it will help improve openness and reward innovation, rather than iterative developments - which have become all too common.
The benefits of Real World Data are that they will help integrate stakeholders allowing each to better utilising these data; whilst certain professions will argue they have been using data from the real world for many years, it is only now that the industry is beginning to harmonise and appreciate how individuals in different roles can work together and make use of this additional information - without question developments in technology have played a huge role in this.
It is clear from the research conducted that industry professionals (of all levels) are becoming focussed on Real World Data, with over 70% of those surveyed expecting their time spent working with RWD to increase over the next 2 years. This anticipation of change is what has really driven the publication of this report which aims to raise industry knowledge across areas which have been identified by the most challenging by those within the industry.
The report provides a comprehensive assessment of the key challenges, opportunities, and disruptive influences associated with real world data and how these are affecting the pharmaceutical business model. Key opinion leaders from the US and Europe have been interviewed in depth to provide these exclusive insights.
Additional to those who were interviewed to build content for this report, we would also like to extend our sincere thanks to the following for reviewing and offering their opinion on the report. This has been invaluable, as it has helped shape the direction allowing us to expand on certain areas.
The eyeforpharma Real World Data (RWD) Report, 2013, was based on 4 months' research involving 34 in-depth interviews with decision makers based in Europe and North America, an exclusive survey on RWD and detailed secondary research on papers published within the past 2 years, as well as those which were referred to by interviewees.
Figure 3: Distribution of job function in initial interviews
Table 3: Distribution of job function in initial interviews
Source: eyeforpharma survey (n=68), 2012
In order to get an accurate feel for RWD within the pharmaceutical industry we initially conducted 21 interviews with industry leaders. The interviews were used to understand current market trends and helped capture qualitative information by using open-ended questions. Given how new this topic is to many people, we focused on the key challenges and needs going forward to understand what topics the report needed to focus on in order to add value.
Figure 4: Most valuable data analytics services and partnerships
Table 4: Most valuable data analytics services and partnerships
|Data analytic service/partnership||%|
|Solution providers / Consultants||59.1|
|Payors / Providers||12.1|
Source: eyeforpharma survey (n=65), 2012
Initial interviewees were selected based on their previous involvement with eyeforpharma - all interviewees were based in Europe and North America: 11 were from pharmaceutical companies, 3 were consultants, 2 vendors, 1 payor, 3 academics and 1 was a healthcare professional.
Figure 5: Primary job function
Table 5: Primary job function
Source: eyeforpharma survey (n=75), 2012
Having established there was a need for business intelligence relating to RWD, various stakeholders were identified as holding valuable insights (figure 3):
Figure 6: ‘Businesses’ primary function'
Table 6: ‘Businesses’ primary function'
|Organisation's primary business||%|
|Pharma / Biotech Company||36.2|
|Consultant / Vendor / Supplier||50.7|
|Academic / Researcher||4.3|
|HTA / Regulator / Insurer||2.9|
Source: eyeforpharma survey (n=75), 2012
A survey was sent out to a targeted section of our database (pharmacists, clinical trials managers, payors, marketing directors, R&D, and medical directors from across the globe) (figure 5). Of these, there was a fairly even distribution of primary job functions, with the majority of those completing the survey coming from top level management (figure 6).
Surveys were distributed electronically in December 2012 and the questions asked were based on:
Having conducted the initial interviews, a survey, a review of additional datasets, literature and conference proceedings pertaining to RWD usage, a decision was made to conduct a further 13 interviews with key figures who have been involved in the development of RWD in the pharmaceutical industry (from the main stakeholders), most of whom are acknowledged in this report.
The additional interviews were very focused and structured around questions which had been identified as business-critical in both the initial interviews and surveys. Interviewees were asked to openly share their thoughts, ideas and personal experiences surrounding the questions asked (see appendix A), and, where possible, were asked to provide case studies to help contextualize a particular subject.
Once the information had been collected it was integrated to uncover the industry trends which are discussed and presented in this report. Key findings have been presented in the form of chapters and case studies and, where relevant, contributors are quoted with examples given in their particular case.
Finally, the report was sent out to 3 peer reviewers who were independent of the project to receive their unbiased opinion on what had been produced.